Romiplostim (Mechanism of Action)

In this article, we will discuss Romiplostim (Mechanism of Action). So, let’s get started.

Mechanism of Action

Romiplostim increases platelet production through binding and activation of the TPO receptor, a mechanism analogous to
endogenous TPO.

Pharmacodynamics

In clinical studies, treatment with Romiplostim resulted in dose-dependent increases in platelet counts. After a single subcutaneous dose of 1 to 10 mcg/kg Romiplostim in patients with chronic ITP, the peak platelet count was 1.3 to 14.9 times greater than the baseline platelet count over a 2- to 3-week period. The platelet counts were above 50 × 109/L for seven out of eight patients with chronic ITP who received six weekly doses of Romiplostim at 1 mcg/kg.

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.